UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related Symptoms

Clinical cancer research, 2016-04, Vol.22 (7), p.1553-1558

2016

Volltextzugriff (PDF)

Regulatory considerations on endpoints in ovarian cancer drug development

Cancer, 2017-07, Vol.123 (14), p.2604-2608

2017

Volltextzugriff (PDF)

Decoding kinase-adverse event associations for small molecule kinase inhibitors

Nature communications, 2022-07, Vol.13 (1), p.4349-4349, Article 4349

2022

Volltextzugriff (PDF)

From big data to smart data: FDA's INFORMED initiative

Nature reviews. Drug discovery, 2017-02, Vol.16 (5), p.306-306

2017

Volltextzugriff (PDF)

An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted Therapies

Clinical cancer research, 2017-03, Vol.23 (6), p.1368-1372

2017

Volltextzugriff (PDF)

Dose Finding of Small-Molecule Oncology Drugs: Optimization throughout the Development Life Cycle

Clinical cancer research, 2016-06, Vol.22 (11), p.2613-2617

2016

Volltextzugriff (PDF)

CT-based multimodal deep learning for non-invasive overall survival prediction in advanced hepatocellular carcinoma patients treated with immunotherapy

Insights into imaging, 2024-08, Vol.15 (1), p.214-13

2024

Volltextzugriff (PDF)

US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments

Journal of clinical oncology, 2018-04, Vol.36 (12), p.1225-1231

2018

Volltextzugriff (PDF)

Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis

Oncoimmunology, 2020-01, Vol.9 (1), p.1748982

2020

Volltextzugriff (PDF)

Evaluating the potential for digital submission of expedited premarket safety reports to the FDA

Nature reviews. Drug discovery, 2016-09, Vol.15 (10), p.670-671

2016

Volltextzugriff (PDF)

Clinical Development of Cancer Drugs in Combination With External Beam Radiation Therapy: US Food and Drug Administration Perspective

International journal of radiation oncology, biology, physics, 2017-05, Vol.98 (1), p.5-7

2017

Volltextzugriff (PDF)

L‐asparaginase inhibits invasive and angiogenic activity and induces autophagy in ovarian cancer

Journal of cellular and molecular medicine, 2012-10, Vol.16 (10), p.2369-2378

2012

Volltextzugriff (PDF)

FDA analysis of enrollment of older adults in clinical trials for cancer drug registration: A 10-year experience by the U.S. Food and Drug Administration

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.10009-10009

2017

Volltextzugriff (PDF)

Regulatory watch: From big data to smart data: FDA's INFORMED initiative

Nature reviews. Drug discovery, 2017-05, Vol.16 (5), p.306-306

2017

Volltextzugriff (PDF)

Diagnosing leptomeningeal carcinomatosis with negative CSF cytology in advanced prostate cancer

Journal of clinical oncology, 2008-07, Vol.26 (19), p.3281-3284

2008

Volltextzugriff (PDF)

U.S. Food and Drug Administration Approval Summary: Atezolizumab for Metastatic Non-Small Cell Lung Cancer

Clinical cancer research, 2017-08, Vol.23 (16), p.4534-4539

2017

Volltextzugriff (PDF)

FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy

Clinical cancer research, 2015-10, Vol.21 (19), p.4257-4261

2015

Volltextzugriff (PDF)

Setting the Record Straight on FDA Approvals in Oncology

JAMA internal medicine, 2017-08, Vol.177 (8), p.1222

2017

Volltextzugriff (PDF)

FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Clinical cancer research, 2015-11, Vol.21 (21), p.4760-4766

2015

Volltextzugriff (PDF)

FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti‐Angiogenic Therapy and Exploratory Predictive Biomarker Analysis

The oncologist (Dayton, Ohio), 2017-03, Vol.22 (3), p.311-317

2017

Volltextzugriff (PDF)

FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutation-Associated Advanced Ovarian Cancer

Clinical cancer research, 2017-12, Vol.23 (23), p.7165-7170

2017

Volltextzugriff (PDF)

21st Century Cardio-Oncology

JACC. Basic to translational science, 2016-08, Vol.1 (5), p.386-398

2016

Volltextzugriff (PDF)

FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum‐Containing Chemotherapy

The oncologist (Dayton, Ohio), 2017-06, Vol.22 (6), p.743-749

2017

Volltextzugriff (PDF)

FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Clinical cancer research, 2016-10, Vol.22 (20), p.4968-4972

2016

Volltextzugriff (PDF)

Challenges and Opportunities in Dose Finding in Oncology and Immuno‐oncology

Clinical and translational science, 2018-07, Vol.11 (4), p.345-351

2018

Volltextzugriff (PDF)

1 – 25 von 1.969

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieStroke

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.719)
Mit Volltextzugriff
(1.661)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.206)
Life Sciences & Biomedicine
(922)
Humans
(649)
Female
(350)
Male
(333)
Middle Aged
(236)
Aged
(199)
Technology
(195)
Oncology
(188)
Adult
(185)
Physical Sciences
(174)
Biological And Medical Sciences
(166)
Animals
(165)
Medical Sciences
(133)
Treatment Outcome
(102)
Neurosciences & Neurology
(99)
Science & Technology - Other Topics
(99)
Chemistry
(95)
Patients
(89)
Risk Factors
(88)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(13)
... seit 90 Tagen
(30)

Menü

Weitere Dienste

Einstellungen

Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related Symptoms

Regulatory considerations on endpoints in ovarian cancer drug development

Decoding kinase-adverse event associations for small molecule kinase inhibitors

From big data to smart data: FDA's INFORMED initiative

An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted Therapies

Dose Finding of Small-Molecule Oncology Drugs: Optimization throughout the Development Life Cycle

CT-based multimodal deep learning for non-invasive overall survival prediction in advanced hepatocellular carcinoma patients treated with immunotherapy

US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments

Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis

Evaluating the potential for digital submission of expedited premarket safety reports to the FDA

Clinical Development of Cancer Drugs in Combination With External Beam Radiation Therapy: US Food and Drug Administration Perspective

L‐asparaginase inhibits invasive and angiogenic activity and induces autophagy in ovarian cancer

FDA analysis of enrollment of older adults in clinical trials for cancer drug registration: A 10-year experience by the U.S. Food and Drug Administration

Regulatory watch: From big data to smart data: FDA's INFORMED initiative

Diagnosing leptomeningeal carcinomatosis with negative CSF cytology in advanced prostate cancer

U.S. Food and Drug Administration Approval Summary: Atezolizumab for Metastatic Non-Small Cell Lung Cancer

FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy

Setting the Record Straight on FDA Approvals in Oncology

FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer

FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti‐Angiogenic Therapy and Exploratory Predictive Biomarker Analysis

FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutation-Associated Advanced Ovarian Cancer

21st Century Cardio-Oncology

FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum‐Containing Chemotherapy

FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Challenges and Opportunities in Dose Finding in Oncology and Immuno‐oncology

Aktive Filter

Suchergebnisse filtern